{"filings":[{"id":96352,"accession_number":"0001493152-26-018590","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tevogen Bio receives Nasdaq deficiency notices for market value requirements","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tevogen on Apr 16, 2026 it fails $50M minimum market value for listed securities (MVLS).","Second notice on Apr 17, 2026 for failing $15M minimum market value of publicly held shares (MVPHS).","Company has 180 days to regain compliance: MVLS by Oct 13, 2026; MVPHS by Oct 14, 2026.","Compliance requires closing at or above threshold for 10 consecutive business days.","Tevogen may consider transferring to Nasdaq Capital Market but provides no assurance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110179,"accession_number":"0001493152-26-012701","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tevogen Bio regains Nasdaq minimum bid price compliance after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 20, 2026 confirming compliance with Listing Rule 5450(a)(1).","Compliance achieved via 1-for-50 reverse stock split of common stock effective March 6, 2026.","Nasdaq matter now closed; no further delisting risk from this requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110178,"accession_number":"0001493152-26-008786","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Tevogen Bio announces 1-for-50 reverse stock split effective March 6, 2026 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1-for-50; effective 12:01 a.m. March 6, 2026.","Pre-split shares outstanding: 202,416,556 as of March 3, 2026.","Directors and executive officers beneficially own >70% of common stock.","No fractional shares issued; cash paid in lieu based on closing price day before effective date.","Authorized shares unchanged at 800M; symbol TVGN remains; new CUSIP 88165K200."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110177,"accession_number":"0001493152-26-008065","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.","Shareholders authorized reverse stock split at ratio between 1:25 and 1:85, with exact ratio set by Board in its discretion.","Both proposals passed with strong support: 147.8M for plan amendment; 176.3M for reverse split (no broker non-votes on split).","182.4 million shares were represented at the special meeting, ~90.5% of outstanding 201.5M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110176,"accession_number":"0001493152-26-004461","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tevogen Bio board to evaluate potential one-time special cash dividend after unspecified milestones","summary_kind":"llm","event_type":"dividend","confidence":"medium","bullets":["Board intends to evaluate a special cash dividend contingent on future financial milestones (revenue, earnings targets).","No dividend has been declared; any declaration subject to financial performance, solvency laws, and board approval.","No assurance can be given on timing, amount, or whether a dividend will occur at all.","Company plans to provide further updates as appropriate under disclosure requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143526,"accession_number":"0001493152-25-015784","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.","Common stock closing bid below $1.00 for 30 consecutive business days; no immediate impact on listing.","Has 180 days (until March 23, 2026) to regain compliance by closing at $1.00+ for at least 10 consecutive days.","If not cured, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","Company will monitor bid price and evaluate options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143525,"accession_number":"0001641172-25-018533","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tevogen Bio grants 8M restricted shares to CEO; total outstanding 193.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved restricted stock awards on June 27, 2025, including 8M shares to CEO Dr. Ryan Saadi.","Total outstanding shares now 193,693,433.","CEO's shares vest in four equal annual installments starting on the seventh anniversary of grant.","Other grantees' shares vest in three equal annual installments starting on the fifth anniversary.","Shares subject to forfeiture if continuous service not maintained; cannot be transferred before vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143524,"accession_number":"0001641172-25-017873","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tevogen Bio enters $50M at-the-market equity sales agreement with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement allows issuance and sale of up to $50M of common stock from time to time.","Sales will be made through A.G.P./Alliance Global Partners as agent at market prices.","Offering conducted under effective shelf registration statement (File No. 333-288218).","Company pays agent a commission on gross proceeds and provides customary indemnification.","Company is not obligated to sell any shares and may terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161717,"accession_number":"0001641172-25-017198","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO Ryan Saadi contributes $500,000 to Tevogen Bio for new HQ costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Founder and CEO Ryan Saadi contributed $500,000 cash to Tevogen Bio on June 30, 2025.","Contribution earmarked for build-out and first-year operating costs of new Warren, NJ headquarters.","CEO personally funding corporate infrastructure expansion, signaling insider commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161716,"accession_number":"0001641172-25-016126","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect Feike and Patton as Class I directors; ratify KPMG as auditor.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey Feike received 150,304,146 votes for and 652,203 against; Dr. Curtis Patton: 150,313,660 for, 647,811 against.","Ratification of KPMG LLP as independent auditor for FY2025: 167,188,556 for, 92,456 against, 79,574 abstentions.","Annual Meeting held June 23, 2025; quorum of 167,360,586 shares (91% of outstanding) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161715,"accession_number":"0001641172-25-013396","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tevogen Bio doubles HQ leased space to 13,242 RSF; lease extended to Feb 2033","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease amendment doubles space from 6,708 to 13,242 rentable square feet on Building's 2nd floor.","Term extended seven years to February 28, 2033; annual base rent approx. $330,000 ($24.75/RSF).","Relocation from 4th floor to 2nd floor effective June 1, 2025; prior lease terminated.","Employees from Philadelphia R&D center to be relocated after its lease expires June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161714,"accession_number":"0001641172-25-006227","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tevogen Bio amends Bylaws to modify director resignation procedure for majority vote failures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended Bylaws on April 21, 2025 to alter process for director resignations when director fails to receive majority vote in uncontested election.","Amendment filed as Exhibit 3.1; no other changes to Bylaws or fiscal year announced.","Procedural governance amendment with no immediate financial or operational impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161713,"accession_number":"0001641172-25-005236","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tevogen Bio inks related-party facility deal with CD8 for cell therapy production","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.","Tevogen to provide primary staff and operations; facility supports both pre-clinical research and GMP production.","Initial term of 12 months, auto-renewing; specific costs, scope, and timelines to be set in future work orders.","Agreement formalizes previously announced letter of intent and aligns with previously stated topline forecasts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179815,"accession_number":"0001493152-25-004002","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tevogen Bio receives $2M grant from KRHP LLC; up to $10M non-dilutive funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $2M grant from KRHP LLC; additional $8M contingent on KRHP's review of activities.","Funding is non-dilutive and will support development of off-the-shelf T cell therapies for cancers and viral infections.","Tevogen may also use grant to expand AI efforts (Tevogen.AI) in partnership with Microsoft.","KRHP LLC is affiliated with spouse of Dr. Manmohan Patel, an existing >5% beneficial owner of TVGN common stock.","Grant is in addition to previously announced $36M loan agreement from Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212879,"accession_number":"0001493152-24-033873","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-08-26T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Tevogen Bio raises $6M via Series C Preferred Stock; two closings Aug 30 & Sept 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor to purchase 600 shares of Series C Preferred Stock for $6.0 million aggregate.","First closing of $4.0M on Aug 30, 2024; second closing of $2.0M on Sept 16, 2024.","Conversion price: VWAP over 30 trading days prior to conversion, floor $0.6172; subject to 9.99% beneficial ownership limit.","Preferred stock carries 7.5% annual cumulative dividend, payable in kind or cash, starting Sept 30, 2024.","Company has call right after five years; stock is non-voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212880,"accession_number":"0001493152-24-033756","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","9.01"],"status":"ready","headline":"Tevogen Bio raises $6M via Series C Preferred; director Suren Ajjarapu resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 600 shares of Series C Preferred at $10,000 each for $6.0M aggregate to The Patel Family, LLP.","Series C carries 7.5% annual cumulative dividend, convertible after 6 months at VWAP floor $0.6172.","Conversion subject to 9.99% beneficial ownership limitation; pre-funded warrants issued if exceeded.","Director Suren Ajjarapu resigned effective August 21, 2024, with no disagreement with the company.","Proceeds from unregistered sale used for general corporate purposes; stock not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231951,"accession_number":"0001493152-24-024727","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","1.02","3.01","9.01"],"status":"ready","headline":"Tevogen Bio receives Nasdaq bid price deficiency notice, repurchases Series B Preferred Stock","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 14, 2024, for non-compliance with $1.00 minimum bid price rule for 35 consecutive business days.","Company has 180 days until December 11, 2024, to regain compliance by closing bid price at $1.00 or more for 10 consecutive days.","Repurchased all 3,613 shares of Series B Preferred Stock from SSVK Associates LLC on June 15, 2024, reassuming $3.6 million liabilities.","Suren Ajjarapu, managing member of SSVK, is a board member; SSVK owns over 5% of common stock.","Repurchase cancelled all outstanding Series B Preferred Stock; related Assignment and Assumption Agreement terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231950,"accession_number":"0001493152-24-023483","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Tevogen Bio secures $36M unsecured credit line from 5% owner Patel Family; equity-linked terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement with The Patel Family LLP (affiliate of 5% holder Manmohan Patel) for up to $36M unsecured facility.","Monthly draws up to $1M; interest is lower of SOFR+2% or 7%, payable quarterly in shares at $1.50/share.","Repayment in cash or stock at greater of $1.50 or 10-day VWAP; maturity 48 months per draw.","Lender gets option to buy $14M+ in stock at 30% discount to VWAP when stock hits $10 (PIPE).","Issuance capped at 19.99% of shares without stockholder consent; 1M commitment shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231945,"accession_number":"0001493152-24-021990","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-05-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Tevogen Bio Inc reports 2023 net loss of $60.5M; cash only $1.05M, going concern raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $60.5M in 2023 ($2.44/share) vs $22.0M in 2022; no revenue.","Operating expenses $8.8M; $50.4M non-cash loss from change in fair value of convertible notes.","Accumulated deficit $99.7M; cash $1.05M at Dec 31, 2023.","Auditors express substantial doubt about ability to continue as going concern.","Post-balance sheet: $2M Series A Preferred (Feb 2024) and $1.2M Series A-1 Preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231949,"accession_number":"0001493152-24-020275","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tevogen Bio enters $36M line of credit with Patel Family; also grants PIPE option for $14M+","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Line of credit up to $36M, draws limited to $1M per month; interest lower of SOFR+2% or 7%.","Interest payable in common shares at $1.50/share; principal due 48 months after draw; prepayment without penalty in cash or stock.","Lender gets option to buy $14M+ in common stock at 30% discount to 10-day VWAP when TVGN hits $10/share.","Commitment fee of 1M shares to be issued upon signing definitive agreement by June 14, 2024.","Patel Family, LLP is an affiliate of 5% holder Manmohan Patel; beneficial ownership limited to 9.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231948,"accession_number":"0001493152-24-017597","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Tevogen Bio Holdings appoints KPMG as auditor, dismisses Marcum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee appointed KPMG as independent auditor for FY2024, effective immediately.","Marcum dismissed as auditor; its prior reports contained a going-concern explanatory paragraph.","Company disclosed a material weakness in internal controls over complex financial instruments and related-party collectability.","No disagreements or reportable events with Marcum; Marcum provided a letter agreeing with disclosures.","KPMG had served as auditor for Tevogen Bio Inc. prior to the June 2023 business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231944,"accession_number":"0001493152-24-016797","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K/A","filed_at":"2024-04-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.","Cash of $1.05M as of Dec 31, 2023; management cites substantial doubt about going concern.","Convertible promissory notes total $94.9M, with $80.7M current; fair value change of $50.4M recorded as loss.","Total operating expenses $8.8M (R&D $4.4M, G&A $4.4M), down from $13.7M in 2022.","Business combination with Semper Paratus closed Feb 14, 2024; post-merger financing included $2M Series A and $1.2M Series A-1 preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231947,"accession_number":"0001493152-24-016060","cik":1860871,"company_name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tevogen Bio expects to eliminate $94.9M liabilities via note conversion; launches AI initiative, appoints new leaders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.","Pro forma balance sheet shows no remaining convertible note liabilities; $80.7M current and $14.2M long-term removed.","Operating expenses for Tevogen Bio Inc. in 2023 were $8.8M, primarily non-cash charges from note fair value changes.","Launches Tevogen.ai AI initiative to enhance drug discovery, manufacturing, and patient access; Mittul Mehta appointed CIO.","Appoints Tapan V. Shah as Head of Investor Relations and Corporate Development; 25-year Wall Street veteran."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28663471.725000005,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}